{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-085185","form_type":"8-K","ticker":null,"cik":"0001845459","company_name":"NKGen Biotech, Inc.","filed_at":"2024-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.008569+00:00","generated_at":"2026-05-30T20:39:56.701544+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"NKGen Biotech appoints Michael Klowden and Kathleen Scott as directors","bullets":["Michael Klowden appointed Class II director until 2025 annual meeting; also joins Audit and Compensation Committees and chairs N&CG Committee.","Kathleen Scott appointed Class III director until 2026 annual meeting; chairs Audit and Compensation Committees and serves on N&CG Committee.","Both directors will receive deferred non-employee director compensation, paid when Company meets funding goals.","No arrangements or related transactions exist between new directors and Company per Reg S-K Item 404(a)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-085185","json":"https://secwatch.observer/filing/0001213900-24-085185.json","markdown":"https://secwatch.observer/filing/0001213900-24-085185.md","text":"https://secwatch.observer/filing/0001213900-24-085185.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1845459/000121390024085185/0001213900-24-085185-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1845459/000121390024085185/ea0216761-8k_nkgen.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T20:39:56.701544+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"78717d9c2e","claim":"Kathleen Scott was elected as Director at NKGen Biotech, Inc..","evidence_excerpt":"The Board following a recommendation from the N&CG Committee, also unanimously elected to have Kathleen Scott fill, effective immediately, the Class III director vacancy created by her resignation","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845459/000121390024085185/0001213900-24-085185-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"97a1297f60","claim":"Michael Klowden was elected as Director at NKGen Biotech, Inc..","evidence_excerpt":"On October 3, 2024, the Board of Directors (the “Board”) of NKGen Biotech Inc. (the “Company”), following a recommendation from the Nomination and Corporate Governance Committee (the “N&CG Committee”), unanimously elected to have Michael Klowden fill, effective immediately, the Class II director vacancy","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845459/000121390024085185/0001213900-24-085185-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}